Bayer exercises option on Micromet BiTE antibody
This article was originally published in Scrip
Executive Summary
Bayer Schering Pharma has licensed an anticancer antibody from Micromet, under a deal signed between the two companies in January. Bayer's exercise of its option to license a specific antibody before January 5th, 2010, has triggered a formal collaboration to develop the product, which was generated using Micromet's BiTE antibody technology.